Boston, Ma., (July 09, 2019) – Joslin Diabetes Center, an affiliate of Harvard Medical School, announced that Susan Dacey, CEO and Chair of the Board of Directors for Industrial Polymers and Chemicals, Inc. in Shrewsbury, has been elected to the Joslin Board of Trustees.
“We are very pleased to welcome Susan Dacey to our Board of Trustees,” said Peter Amenta, M.D., Ph.D., President and CEO of Joslin Diabetes Center. “Susan has extensive business leadership experience as CEO and Board of Directors Chair of Industrial Polymers and Chemicals, Inc. (IPAC). She will add critical perspectives to our board and support us in our mission to improve the lives of those living with diabetes through innovative research and clinical care. We look forward to working with Susan.”
Susan Dacey currently serves as CEO and Chair of the Board of Directors Chair for Industrial Polymers and Chemicals, Inc., having acted as President and CEO of the company since 1996. In 2000, under Susan’s leadership, IPAC purchased the former Quinco Fabrics to become the only totally integrated manufacturer of fiberglass reinforcements. In addition to her current role, Dacey is Board of Trustees President with The Massachusetts Manufacturing Self-Insurance Group and works in commercial real estate.
Ms. Dacey was elected to a three-year term at the June Board of Trustees meeting.
About Joslin Diabetes Center
Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 16 NIH-designated Diabetes Research Centers in the U.S.